AstraZeneca: AI is Shaping the Biopharmaceuticals Industry

AI is revolutionising industries, and biopharmaceuticals is no different. 

AstraZeneca is at the forefront of leveraging AI to transform biopharmaceutical research and development. With AI-enabled drug discovery systems, AstraZeneca accelerates the creation of novel therapeutic molecules from years to weeks, targeting diseases that were previously considered ‘undruggable’.

Its AI-driven platform integrates across the entire value chain – from early target identification and molecule design to clinical development optimisation and real-world evidence integration – demonstrating systematic transformation rather than incremental improvements.

The company’s strategic adoption of AI is highlighted by its use of Gen AI to create entirely new biologic molecules such as antibodies and proteins with tailored therapeutic properties, a breakthrough capability that underpins AstraZeneca’s innovation pipeline and competitive edge. 

With AI acting as a predictive and generative partner to researchers – enhancing human expertise without replacing it – AstraZeneca is enabling smarter molecule design, predictive safety assessments and adaptive trial designs. 

Dr Santosh Karthikeyan Viswanathan, Global Technical Director of Clinical Data & Insights at AstraZeneca, will present a keynote at Tech & AI LIVE Singapore on November 4, 2025 discussing real-world AI use cases across biopharma. 

Secure your place at Tech & AI LIVE Singapore here.

His session covers how AI reshapes drug discovery, clinical trials, manufacturing efficiency and patient outcomes, alongside key considerations for ethical AI adoption, data governance, model interpretability and cross-functional collaboration within regulated environments.

AI-driven drug discovery

AstraZeneca’s approach to AI exemplifies the future of biopharmaceutical R&D: a data-driven, AI-augmented, scientifically rigorous model poised to deliver breakthrough therapies faster and more reliably than ever before, advancing patient care worldwide

For example, the company’s AI system generates innovative therapeutic molecules rapidly by understanding complex biological relationships and predicting molecular behaviour with precision.

This eliminates traditional trial-and-error inefficiencies and targets previously untreatable diseases like chronic kidney disease and idiopathic pulmonary fibrosis.

AI designs compounds optimising efficacy, safety and manufacturability from the outset, reducing development risk.​

AI: Integrated across the entire value chain

AI is embedded throughout AstraZeneca’s research phases – from target identification through clinical trial optimisation and regulatory strategy. 

The AI analyses vast scientific data networks, enabling discovery of novel intervention points and accelerating trial designs that adapt dynamically based on data insights.

Real-world clinical data feedback closes development loops, validating AI predictions and improving therapeutic success rates.​​

This does not mean that the human element is eradicated, though.

Acting as a ‘thought partner’ – as Dr Viswanathan will emphasise in his AI in BioPharmaceuticals: Industry Use Cases and Key Considerations keynote at Tech & AI LIVE Singapore – AI augments human decision-making rather than replacing researchers. 

Secure your place now and join the conversation at Tech & AI LIVE Singapore.

AstraZeneca maintains scientific rigour and regulatory compliance by integrating AI insights with expert human judgment. 

Ethical adoption principles around data governance and model transparency guide sustainable AI use in highly regulated biopharma environments.

AstraZeneca at Tech & AI LIVE Singapore

At Tech & AI LIVE Singapore, Dr Viswanathan will take to the virtual stage to share insights on AI-driven innovation shaping biopharmaceuticals. 

He will illustrate how AI sets new standards in smarter molecule design, predictive safety assessments, adaptive clinical trials and supply chain resilience, while addressing the practical challenges of scalable, ethical AI adoption in R&D and operations.​

Tech & AI LIVE Singapore is designed to bring together the most influential technology and artificial intelligence leaders from across APAC, providing a dynamic platform for decision-makers, disruptors and digital leaders to connect, share insights, explore cutting-edge solutions and drive digital transformation and AI adoption.

Join Tech & AI LIVE Singapore 2025 on 4 November by securing your free ticket here.